Skip to NavigationSkip to content

UCB Pharma

New Phase 3 data confirms safety and efficacy of UCB's Cimzia in plaque and psoriatic arthritis

New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment of moderate-to-severe plaque psoriasis, and its efficacy in patients showing signs of psoriasis-related nail disease and those showed an inadequate early treatment response to the drug.

The first 96 weeks of data derived from 995 participants across two ongoing Phase 3 studies demonstrated that “confirmed the long-term safety of Cimzia in the treatment of psoriasis”, with no new safety concerns flagged, while the overall incidence of adverse events was low.

NICE recommends UCB's Cimzia in severe plaque psoriasis

NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in the treatment of severe plaque psoriasis in patients who have failed to respond to, or are unsuitable for, other systemic treatments.

The judgement also adds an additional treatment option for women before or during pregnancy, as well as while breastfeeding.

FDA green lights Amgen and UCB's Evenity in postmenopausal osteoporosis patients

The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at high risk of fracture, it has been revealed.

According to the manufacturers, Evenity is the “first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture”.

UCB teams up with charity to beat treatment-resistant epilepsy in $2.5m partnership

Belgian firm UCB Pharma has announced a new partnership with the charity Epilepsy Society which will see the pair invest $2.5 million over the next five years as part of a project to develop greater understanding of the pathology of epilepsy and how to effectively treat treatment-resistant patients with the condition.

Both partners chose to launch the collaboration on 11 February to mark International Epilepsy Day.

Amgen and UCB's Evenity approved in Japan for osteoporosis

Image Credit: National Osteoporosis Foundation

Amgen has revealed that its bone-forming monoclonal antibody Evenity (romosozumab), developed in partnership with UCB Pharma, has been awarded approval in Japan for the treatment of osteoporosis in patients at high risk of fracture.

The decision, which precedes final verdicts in the US and Europe, where review is currently ongoing, was based on Phase 3 data from two studies encompassing 7,180 postmenopausal women and 245 men with osteoporosis, finding the drug to be both safe and effective following a robust review.

UCB targets regulatory filing for its osteoporosis drug in 2016

UCB chief executive, Jean-Christophe Tellier, revealed drug met primary endpoints in Phase III trials

Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis in postmenopausal women. The company recently announced late-stage trials for the drug candidate met the primary end point and is looking at announcing further data in September.

Romosozumab is a trial stage bone-forming monoclonal antibody and is not approved by any regulatory authority for the treatment of osteoporosis.

New epilepsy drug launches in UK

UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary generalised seizures in adults with epilepsy, offering an additional treatment option for UK patients.

In an international Phase III study of 768 patients uncontrolled on their previous medication, Briviact was shown to give significant seizure freedom over placebo, compared with the patients’ usual medication.

AbbVie VP joins UCB Pharma

Published on: 25/01/16

Pascale Richetta will join the UCB as its new head of the bone therapy patient value unit as from February 1, 2016.

Richetta has had a 20 year career in the pharma industry, and has commercial experience managing traditional pharmaceuticals and complex biologics. She joins UCB from Abbvie, where she was vice president of Western Europe and Canada. Prior to this she held several management positions at Abbott, GSK, Ipsen and Servier, successfully launching these companies’ key drugs on several international markets.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches